))
Fred Vogt, Iovance Biotherapeutics
Manage episode 468650021 series 3347911
Content provided by Life Sciences Pennsylvania. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences Pennsylvania or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award.
In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.
61 episodes
Share
